Aggressive multi ‐combination therapy for anti‐MDA5 antibody‐positive dermatomyositis‐rapidly progressive interstitial lung disease

ConclusionThis aggressive multi-combination therapy may improve the survival outcome of patients with anti-MDA5 antibody-positive DM-RPILD. However, careful management of complications, such as opportunistic infections and leukopenia, is essential. Future refinement through longitudinal investigations tracking the long-term efficacy, safety, and cost-effectiveness of this treatment strategy is needed.

Source: International Journal of Rheumatic Diseases - December 9, 2023 Category: Rheumatology Authors: Kenichiro Hata, Takuya Kotani, Shogo Matsuda, Youhei Fujiki, Takayasu Suzuka, Takao Kiboshi, Yumiko Wada, Hideyuki Shiba, Takeshi Shoda, Maki Kagitani, Tohru Takeuchi Tags: ORIGINAL ARTICLE Source Type: research